Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M

ZEVRA THERAPEUTICS, INC.

2026-Q1 EPS reported -$0.06 vs consensus $0.08 ▼ miss (-172.8%)

Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.
Net loss of $3.1M ($0.06 per share) vs. $16.6M loss ($0.40) in Q1 2024; operating expenses $22.8M.
Closed sale of Pediatric Rare Disease PRV for $150M gross; net proceeds $148.3M received Apr. 1, 2025.
Cash, equivalents and investments $68.7M at Mar 31; combined with PRV proceeds, pro-forma cash $217M.
MIPLYFFA: 13 new prescription enrollment forms in Q1 (122 total); market access 38% of covered lives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.